Why Docusign Stock Got Devastated Today

Docusign shares fell nearly 20% despite Q1 FY2026 earnings beating estimates with adjusted EPS of $0.90 on revenue of $764 million, as billings growth slowed to 4% and free cash flow declined year-over-year to $227.8 million. The disappointing market reaction stems from concerns over slowing growth, with the company projecting only 6% revenue growth for Q2 and the full year, overshadowing improved gross profit margins and GAAP earnings.

Analysis

Docusign (DOCU) experienced a significant stock price decline of 19.3% despite reporting fiscal Q1 2026 earnings that surpassed analyst expectations on both revenue and adjusted earnings per share. The company posted adjusted EPS of $0.90, exceeding the $0.81 forecast, on revenues of nearly $764 million, versus an anticipated $750 million. While Q1 sales grew 8% year-over-year and GAAP diluted earnings more than doubled to $0.34 per share, accompanied by a 50 basis point improvement in gross profit margins to 79.4%, critical forward-looking indicators raised concerns. Billings, a key metric for future revenue, grew only 4%, and more notably, free cash flow (FCF) declined to $227.8 million from $232.1 million in the prior year period. This contraction in FCF, coupled with the modest billings growth, appears to have overshadowed the earnings beat. Docusign's guidance further fueled investor apprehension, projecting Q2 sales growth to slow to 6%, translating to approximately $779 million in revenue, with full-year growth also guided at a similar 6% rate, or $3.15 billion to $3.16 billion in annual sales. This deceleration suggests a challenging growth trajectory for a company historically viewed as a growth stock. Despite these headwinds, the stock trades at a 16.6 times trailing FCF multiple, which is presented as an 'unchallenging valuation,' particularly when considering the company's net cash position.

Key Decisions for Investors

• Investors should scrutinize Docusign's upcoming billings growth figures and free cash flow generation in subsequent quarters, as these are pivotal indicators of a potential growth re-acceleration or further deceleration.
• Despite the sharp stock price decline and a seemingly modest valuation on a trailing FCF basis, the company's own guidance for 6% revenue growth presents a significant concern for future appreciation, warranting caution.
• Given the strongly negative market reaction and conservative forward guidance, it may be prudent for investors to await tangible evidence of a sustained improvement in growth metrics before initiating or adding to positions, especially as the company was not highlighted as a top pick by the cited analyst team.